FDA Issues Final Guidance Urging Less Restrictive Cancer Trial Eligibility Rules, Potentially Opening More Studies to Medicare-Age Patients

The Food and Drug Administration issued final guidance on July 27, 2026, recommending that sponsors of cancer clinical trials adopt less restrictive eligibility criteria in two areas: washout periods, which require patients to stop a current medication for a set interval before joining a trial, and concomitant medication restrictions, which bar patients taking certain other treatments from participating. The FDA concluded that many trials have set these thresholds more conservatively than evidence supports, excluding patients without a meaningful safety or scientific benefit.

The guidance is part of a multi-year FDA initiative to broaden the representativeness of cancer research populations. Older adults, people with more than one medical condition, and people who take multiple medications have historically been excluded from trials at elevated rates. That profile matches a large share of Medicare beneficiaries.

Medicare covers routine care costs for beneficiaries who enroll in qualifying clinical trials, including standard office visits, laboratory tests, and required hospital stays. When trial eligibility criteria become less restrictive, more Medicare patients can potentially qualify for those studies and retain that coverage for their standard care during the trial. A companion FDA guidance on performance status eligibility criteria was also released on the same date, continuing the agency's multi-document effort to modernize trial design. Neither guidance changes Medicare's own payment or coverage rules; the effect is to encourage trial designers to remove gatekeeping criteria that lack a clear scientific or safety justification.